(IN BRIEF) The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO, a novel factor VIII replacement therapy used to control bleeding in patients with hemophilia A. ALTUVIIIO, also known as efanesoctocog alfa, stands out … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science
Tagged ALTUVIIIO, authorization, bleeding, Brian Foard, efanesoctocog alfa, FDA, hemophilia A, Japan, marketing, MHLW, partnership, Sanofi, Sobi, treatment
(IN BRIEF) Sanofi has simplified its contractual arrangements with AstraZeneca and Sobi for the development and commercialization of Beyfortus (nirsevimab) in the United States. Under the new arrangements, Sanofi will have full commercial control of nirsevimab in the U.S. Sanofi … Read the full press release
Posted in Business, France, Healthcare, Industrial, Management, News, Pharma & Biotech
Tagged AstraZeneca, Beyfortus, commercialization, contractual agreements, nirsevimab, partnership, Sanofi, Sobi, USA
(PRESS RELEASE) STOCKHOLM, 2-Sep-2021 — /EuropaWire/ — Investor AB (STO: INVE-B), a Swedish investment and holding company founded in 1916, has announced its support for the Agnafit Bidco¹’s bid for Sobi (Swedish Orphan Biovitrum AB). The company has undertaken to … Read the full press release
Posted in Business, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged acquisitions, Advent International, Advent International Corporation, Agnafit Bidco, Aurora Investments Pte Ltd, Biovitrum, GIC Pte Ltd., GIC Special Investments Pte Ltd, Healthcare, hematology, hemophilia, immunology, Investor AB, Johan Forssell, public offer, shares, Sobi, Swedish Orphan Biovitrum AB, Swedish Orphan International
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
